How Analysts View Pfizer and Merck After Earnings
After Pfizer and Merck released their most recent earnings reports last week, analysts weighed in on both of these pharmaceutical giants.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 226
How Analysts Value Gilead Now After Earnings
After Gilead Sciences reported fourth-quarter financial results on Tuesday, analysts weighed in on this biotech giant and in what direction it might go next.
Top 4 BioPharma Movers of the Week
Over the past week, Alere and a few biotech other companies made absolutely massive runs, either up and down.
Party City and Staples Partner Up in E-Commerce Deal
Party City has announced an e-commerce fulfillment relationship with Staples to expand into the e-commerce space.
Mapi Pharma Closes in on IPO
Mapi Pharma expects to price more than 3 million shares in the range of $15 to $17 in an initial public offering valued up to about $61 million.
Quotient Gears Up for Secondary Offering
Quotient led the bulls going into Friday’s trading session on news of a secondary offering.
Why TherapeuticsMD Could Still Rise Almost 200%
TherapeuticsMD shares were active on Thursday after an analyst report suggested that the stock could have up to almost 200% upside.
Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pet’s Health
Credit Suisse made a point to highlight a few animal health companies that stand to outperform the markets in 2016 and even beyond.
Therapure Biopharma Postpones IPO
Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.
Will Sinovac Go Through With This Buyout?
Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it looks like this company doesn’t want to take the bait. It announced that the…
BeiGene Explodes Into the Market
BeiGene entered the market with a bang on Wednesday in its initial public offering priced at the high end of its expected range.
Editas Announces Final Pricing for IPO
Editas Medicine will price its nearly 6 million shares at $16 apiece in an initial public offering valued at more than $108 million.
Merck Trips Up Over Mixed Earnings
Merck reported mixed fourth-quarter financial results before the markets opened Wednesday.
Gilead Rises on Solid HCV Sales and Earnings Beat
Gilead Sciences reported better-than-expected fourth-quarter financial results after the markets closed on Tuesday.
What Expect From Gilead Earnings
Gilead Sciences is set to release its fourth-quarter earnings report after the markets close on Tuesday.